311 related articles for article (PubMed ID: 28678566)
1. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Wang GH; Svensson M; Shao H; Vouri SM; Park H
J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
[No Abstract] [Full Text] [Related]
5. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
Basu A; Benson C; Alphs L
J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
[TBL] [Abstract][Full Text] [Related]
6. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates.
Nuhoho S; Saad A; Saumell G; Ribes D; El Khoury AC
Curr Med Res Opin; 2018 Apr; 34(4):601-611. PubMed ID: 29292670
[TBL] [Abstract][Full Text] [Related]
9. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
[TBL] [Abstract][Full Text] [Related]
10. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
Joshi K; Lin J; Lingohr-Smith M; Fu DJ
J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
[TBL] [Abstract][Full Text] [Related]
11. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
[TBL] [Abstract][Full Text] [Related]
13. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections.
Debaveye S; De Smedt D; Heirman B; Kavanagh S; Dewulf J
BMC Health Serv Res; 2019 Jun; 19(1):393. PubMed ID: 31217000
[TBL] [Abstract][Full Text] [Related]
14. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
16. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of using paliperidone palmitate in schizophrenia in China.
Luo R; Lu H; Li H
Front Pharmacol; 2023; 14():1238028. PubMed ID: 37601057
[No Abstract] [Full Text] [Related]
19. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
[TBL] [Abstract][Full Text] [Related]
20. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
[No Abstract] [Full Text] [Related]
[Next] [New Search]
